Adverum Biotechnologies (ADVM) has released the 26-week interim analysis results from the LUNA Phase 2 trial of Ixo-vec, aimed at treating patients with wet age-related macular degeneration. The company revealed that the analysis highlights Ixo-vec's potential to be a best-in-class product, boasting both a favorable safety profile and a significant proportion of patients who require no further injections. These findings support the decision to proceed with the 6E10 dose and a local prophylactic regimen in forthcoming Phase 3 pivotal studies. Adverum plans to present additional data at the nine-month and one-year milestones over the forthcoming quarters.
"The LUNA trial was designed to address a critical question: could lower doses of Ixo-vec, coupled with enhanced prophylactic regimens, yield a product profile equivalent to or superior to that seen in the OPTIC trial? The landmark six-month interim analysis has successfully answered this question," stated Star Seyedkazemi, Adverum's Chief Development Officer.
